In December 2020, Steven Stefanidis, a 36-year-old firefighter from Toronto, was responding to a medical name when he blacked out and had a seizure.
After being assessed by first responders, he was taken to the hospital, the place an MRI revealed a tumour. It was recognized as a Grade 2 IDH-mutant glioma, an incurable type of mind most cancers.
It got here as a whole shock, Stefanidis recounted to World Information.
“Here I was in my early 30s, living my best life with a dream job when I suddenly had a seizure. I can’t describe what it was like to be told that I had an incurable brain cancer,” he mentioned.
“At first I was in shock and I wasn’t digesting the information because it’s heavy. But overall, the neurosurgeon that I met was very relaxed and confident and I trusted him and he put me in a good situation. I didn’t freak out or anything. I knew I was in good hands at the moment.”
He later underwent surgical procedure to alleviate his signs, which befell one week after his analysis.
Steven Stefanidis after his mind surgical procedure.
Steven Stefanidis
Stefanidis is likely one of the 1000’s of Canadians recognized with mind and spinal wire most cancers yearly, in keeping with the Canadian Most cancers Society. The kind he has, gliomas, is the second-most frequent most cancers amongst Canadians beneath 40 and the second-leading reason behind cancer-related deaths on this age group.
And IDH-mutant glioma normally arises in folks of their 30s and 40s, when they’re within the prime of their lives — working and elevating households, defined Dr. Mary Jane Lim-Fats, neurologist and neuro-oncologist at Sunnybrook Well being Sciences Centre.
“There is no current cure for diffuse gliomas in adults,” Lim-Fats advised World Information. “So our best treatments, which up until now have consisted of radiation and chemotherapy, only delay the time until which the tumour grows back. It’s been very challenging to find better treatments for our patients.”
However there may be hope. A brand new oral treatment known as Voranigo has been proven to focus on mind tumours, and in Part 3 scientific trials, to “significantly” gradual their progress. Stefanidis participated in these scientific trials at Sunnybrook Well being Sciences Centre in Toronto, and he mentioned the therapy has been efficient for his most cancers.
“Since receiving the treatment during the clinical trials… there’s no side effects from the medication, and on the positive side, we’ve noticed stabilization and some shrinkage in the remaining [tumour],” he mentioned.
Steven Stefanidis is photographed on the Odette Most cancers Centre at Sunnybrook Well being Sciences Centre Could 24, 2023.
by Kevin Van Paassen/Sunnybrook
And now it has formally been accepted in Canada.
Get weekly well being information
Obtain the newest medical information and well being info delivered to you each Sunday.
On Tuesday, Well being Canada introduced the approval of Voranigo, the primary focused remedy for treating Grade 2 isocitrate dehydrogenase (IDH)-mutant glioma in adults and pediatric sufferers aged 12 and older, following surgical procedure. It’s Canada’s first oral focused therapy for mind most cancers.
Drug slowed development of tumour
Voranigo was studied in a large-scale, randomized, placebo-controlled scientific trial with sufferers from all over the world, together with Canada, from January 2020 by way of February 2022.
The outcomes of the Part 3 scientific trials had been revealed in June 2023 within the New England Journal of Drugs, and present promising outcomes, Lim-Fats mentioned.
“This new drug essentially is a brain penetrant oral drug that patients can take by mouth that alters the function of that mutant protein. So in doing that, it slows down the growth of the tumour, stabilizes it in some instances, and even decreases the growth or shrinks the tumours in some cases,” she mentioned.
So what precisely does this imply?
Gliomas are troublesome to deal with and infrequently progress to extra aggressive types of mind most cancers, partly as a result of blood-brain barrier. This protecting layer shields the mind from hurt but additionally makes it difficult for therapies to penetrate and successfully goal tumours, Lim-Fats defined.
As a result of blood-brain barrier, the present therapy for gilomas entails a mixture of surgical procedure, adopted by radiation and chemotherapy. Whereas these remedies can quickly halt the tumour’s progress, Lim-Fats famous that it will definitely returns.
However Voranigo is particularly designed to cross the blood-brain barrier and attain the mind to focus on mutated enzymes which are inflicting the most cancers.
Part 3 scientific trial outcomes present that the drug greater than doubled the time earlier than the tumour grew again in sufferers. It additionally delayed the necessity for interventions like chemotherapy and radiation, which include extreme uncomfortable side effects.
“The median progression-free survival for patients who were on placebo — so did not receive anything — was roughly about 11.1 months. But when they looked at the group that got [Voranigo], that progression-free survival, that delay was more than double that time, it was 27.7 months,” Lim-Fats mentioned.
“These results in and of themselves are very encouraging and showed that this drug was actually quite good at delaying that progression in these patients.”
‘Major breakthrough’ in most cancers therapy
Now that Voranigo is accepted in Canada, Stefanidis mentioned he hopes the treatment may also help others who’re in the identical scenario.
After taking time without work work, he’s now again on the job as a firefighter and has even began touring, exercising and climbing once more.
“I feel like a regular, normal, healthy adult. I’m slowly back to my regular day-to-day routine. I’m back to work now, fully back on the fire trucks responding. And it feels great to be back on with the same crew,” he mentioned.
“I just recently had my first vacation in July of this year. And it felt amazing just to get out there. And that’s another thing about this medication. It’s not something where I had to stay within my area because I could only get the treatment there. I’m able to carry this with me wherever I go and use it as like a mobile treatment,” he added.
After taking time of labor for his most cancers analysis, Stefanidis is again on the job.
Steven Stefanidis
Stefanidis mentioned he takes it as soon as each morning, just like a multivitamin, and retains observe of it in his diary for dosage and time.
Lim-Fats expressed that the oncology group is really excited concerning the approval of this drug in Canada, saying, “We haven’t had a breakthrough like this in terms of a new drug in about 20 years.”
Nonetheless, she famous that some questions stay. Docs nonetheless don’t know the long-term survival outcomes for sufferers taking the drug, or whether or not sure teams of sufferers would possibly reply higher or longer to the therapy.
“But nonetheless, we think it is a major breakthrough and major advancement in terms of providing more options for patients,” she mentioned.
